



**OUTLINE OF ACTIVE TRIALS WITH SELGANTOLIMOD (GS-9688)
JULY 2021**

Study Title: A Phase 2a, Open-Label Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)

Sponsor: Gilead Sciences, Inc.
333 Lakeside Drive
Foster City
CA 94404
USA

EudraCT Number: 2021-000672-11

Indication: Chronic hepatitis B virus (HBV) infection

Protocol ID: GS-US-465-4439

There are currently no Gilead sponsored Selgantolimod (GS-9688) clinical trials ongoing, approved or under assessment in the European Union.